[The first 'respiration' fluoroquinolone--levofloxacin (Tavanic) in therapy of bacterial infections. Pharmacodynamics principles in optimization of administration regimens].
Budanov
S V
SV
Research Centre of Drug Evaluation and State Control, National Research Centre of Antibiotics, Moscow.
Vasil'ev
A N
AN
Smirnova
L B
LB
D000208:Acute Disease; D000818:Animals; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D001991:Bronchitis / Q000188:drug therapy; D002908:Chronic Disease; D017714:Community-Acquired Infections / Q000188:drug therapy; D006801:Humans; D064704:Levofloxacin; D015523:Maxillary Sinusitis / Q000188:drug therapy; D015242:Ofloxacin / Q000008:administration & dosage / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use; D018410:Pneumonia, Bacterial / Q000188:drug therapy; D012141:Respiratory Tract Infections / Q000188:drug therapy* / Q000378:metabolism; D014552:Urinary Tract Infections / Q000188:drug therapy
D000890:Anti-Infective Agents; D064704:Levofloxacin; D015242:Ofloxacin